Biocon's Research Arm Syngene Reported Net Profit Up by 31% in Q2

Revenue for quarter under review (Q2) grew 28% to Rs. 262 crore from Rs. 205 crore in same period a year ago.

Pharma major Biocon's research arm Syngene International Ltd. has reported a net profit of Rs. 52 crore for second quarter of fiscal 2015-16 from Rs. 40 crore in the same period for 2014-15, posting 31% annual growth.

The subsidiary said in a statement, "Revenue for quarter under review (Q2) grew 28% to Rs. 262 crore from Rs. 205 crore in same period year ago, while earnings before depreciation, income tax and amortization (Ebitda) increased 30% to Rs. 87 crore from Rs. 67 crore year ago."

Dr. Reddy's Laboratories Net Profit Up by 14% in the First Quarter of 2015-16
Total income of the company has increased from Rs. 3,536.02 crore for the quarter ended June 30, 2014 to Rs. 3,770.25 crore for the quarter ended June 30, 2015.

Sequentially, net profit increased 20% to Rs. 52 crore from Rs. 44 crore in first quarter, while revenue was up 11% to Rs. 262 crore from Rs. 236 crore.

Syngene chief executive Peter Bains said, "We have witnessed sustained momentum in our business across our dedicated centers, discovery and development platforms. Capacity expansion in manufacturing services helped the research firm to keep pace with the increasing requirements of the clients worldwide. We continue to invest in the discover and development space to support our partner's evolving needs and to deliver value to our investors."

Source-IANS

Bio-pharmaceutical Company Biocon's Net Profit Surges by 20.23% in 2014-2015
Biocon’s net profits during January-March 2015 surged by 78% at Rs.201.54 crore of which the company got Rs.105 crore by selling some of its stakes in Syngene.

Alcobra Pharma Announces Fourth Quarter and Fiscal Year 2014 Financial Results
Alcobra Pharma has announced financial results for the fourth quarter and fiscal year ended December 31, 2014, and provided a business update.

500 Million Could Be Raised Every Year By Price Cap Regulations for UK Tobacco
A feasibility study reveals that if tobacco products sold in the UK were subject to price cap regulation, the system would generate around £500 million (US$750 million) for the government every year.